A first-of-its-kind human trial is underway to investigate the potential of gene therapy to rejuvenate aging cells. The study centers on “partial reprogramming,” a process aimed at restoring youthful function to cells without fully reverting them to an embryonic state. The initial patient enrolled has glaucoma, a condition affecting the optic nerve, and will be monitored for improvements. Researchers hope this approach could revolutionize regenerative medicine by addressing age-related diseases at a cellular level. While still early, the trial represents a significant step towards potentially reversing the effects of aging. The therapy aims to improve cellular function, rather than simply slowing down the aging process. Results from the trial are expected to provide valuable insights into the safety and efficacy of this novel approach.